Patient and transplant characteristics
| Baseline characteristics . | All . | Cryo . | Fresh . | P-value . |
|---|---|---|---|---|
| Patient/Donor | ||||
| Patient age, median (range) | 64 (21, 79) | 63 (25, 79) | 64 (21, 78) | .4 |
| Patient sex, n (%) | .39 | |||
| Female | 157 (40.6) | 51 (37.5) | 106 (42.4) | |
| Male | 230 (59.4) | 85 (62.5) | 145 (57.8) | |
| Donor age, median (range) | 27 (18, 64) | 28 (19, 64) | 27 (18, 54) | .35 |
| Donor sex, n (%) | .58 | |||
| Female | 142 (36.7) | 47 (34.6) | 95 (37.8) | |
| Male | 245 (63.3) | 89 (65.4) | 156 (62.2) | |
| Female donor in male patient, n (%) | 64 (16.3) | 23 (16.9) | 40 (15.9) | .89 |
| KPS at transplant, n (%) | .74 | |||
| 100-90 | 140 (36.2) | 51 (37.5) | 89 (35.5) | |
| <90 | 247 (63.8) | 85 (62.5) | 162 (64.5) | |
| Disease, n (%) | .96 | |||
| ALL | 45 (11.6) | 17 (12.5) | 28 (11.2) | |
| AML | 144 (37.2) | 48 (35.3) | 96 (38.2) | |
| MDS | 108 (27.9) | 38 (27.9) | 70 (27.9) | |
| MDS/MPN | 2 (0.5) | 1 (0.7) | 1 (0.4) | |
| MPN | 28 (7.2) | 9 (6.6) | 19 (7.6) | |
| NHL | 33 (8.5) | 13 (9.6) | 20 (8) | |
| Other leukemia | 15 (3.9) | 5 (3.7) | 10 (4) | |
| CML | 5 (1.3) | 2 (1.5) | 3 (1.2) | |
| Histiocytosis | 4 (1) | 2 (1.5) | 2 (0.8) | |
| Hemoglobinopathy | 1 (0.3) | 1 (0.7) | 0 (0) | |
| Other Anemia | 1 (0.3) | 0 (0) | 1 (0.4) | |
| Atypical CML | 1 (0.3) | 0 (0) | 1 (0.4) | |
| Recipient/Donor CMV, n (%) | .55 | |||
| R-/D- | 148 (38.2) | 51 (37.5) | 97 (38.6) | |
| R-/D+ | 86 (22.2) | 27 (19.9) | 59 (23.5) | |
| R+/D- | 84 (21.7) | 30 (22.1) | 54 (21.5) | |
| R+/D+ | 68 (17.6) | 27 (19.9) | 41 (16.3) | |
| Not tested | 1 (0.3) | 1 (0.7) | 0 (0) | |
| HCT-CI, n (%) | .65 | |||
| 0 | 12 (3.1) | 6 (4.4) | 6 (2.4) | |
| 1 | 58 (15) | 18 (13.2) | 40 (15.9) | |
| 2 | 56 (14.5) | 19 (14) | 37 (14.7) | |
| ≥3 | 261 (67.4) | 93 (68.4) | 168 (66.9) | |
| Median (range) | 4 (0, 12) | 4 (1, 10) | 4 (0, 12) | |
| Degree of HLA match, n (%) | .24 | |||
| 8/8 | 333 (86) | 122 (89.7) | 211 (84.1) | |
| 7/8 | 52 (13.4) | 13 (9.6) | 39 (15.5) | |
| 6/8 | 2 (0.5) | 1 (0.7) | 1 (0.4) | |
| Transplant characteristics | ||||
| Conditioning intensity, n (%) | .095 | |||
| Myeloablative | 105 (27.1) | 44 (32.4) | 61 (24.3) | |
| Reduced intensity | 282 (72.9) | 92 (67.6) | 190 (75.7) | |
| GVHD prophylaxis regimen, n (%) | .23∗ | |||
| PTCY | 1 (0.3) | 0 (0) | 1 (0.4) | |
| PTCY/Tacrolimus/Mycophenolate mofetil | 76 (19.9) | 32 (23.5) | 43 (17.9) | |
| Tacrolimus/Methotrexate | 238 (61.5) | 90 (66.2) | 148 (59) | |
| Tacrolimus/Rapamycin | 6 (1.6) | 1 (0.7) | 5 (2) | |
| Tacrolimus/Rapamycin/Methotrexate | 66 (16.8) | 13 (9.6) | 53 (20.7) | |
| Duration of cryopreservation (h), median (range) | 272.7 (48.1, 2855,7) | |||
| Baseline characteristics . | All . | Cryo . | Fresh . | P-value . |
|---|---|---|---|---|
| Patient/Donor | ||||
| Patient age, median (range) | 64 (21, 79) | 63 (25, 79) | 64 (21, 78) | .4 |
| Patient sex, n (%) | .39 | |||
| Female | 157 (40.6) | 51 (37.5) | 106 (42.4) | |
| Male | 230 (59.4) | 85 (62.5) | 145 (57.8) | |
| Donor age, median (range) | 27 (18, 64) | 28 (19, 64) | 27 (18, 54) | .35 |
| Donor sex, n (%) | .58 | |||
| Female | 142 (36.7) | 47 (34.6) | 95 (37.8) | |
| Male | 245 (63.3) | 89 (65.4) | 156 (62.2) | |
| Female donor in male patient, n (%) | 64 (16.3) | 23 (16.9) | 40 (15.9) | .89 |
| KPS at transplant, n (%) | .74 | |||
| 100-90 | 140 (36.2) | 51 (37.5) | 89 (35.5) | |
| <90 | 247 (63.8) | 85 (62.5) | 162 (64.5) | |
| Disease, n (%) | .96 | |||
| ALL | 45 (11.6) | 17 (12.5) | 28 (11.2) | |
| AML | 144 (37.2) | 48 (35.3) | 96 (38.2) | |
| MDS | 108 (27.9) | 38 (27.9) | 70 (27.9) | |
| MDS/MPN | 2 (0.5) | 1 (0.7) | 1 (0.4) | |
| MPN | 28 (7.2) | 9 (6.6) | 19 (7.6) | |
| NHL | 33 (8.5) | 13 (9.6) | 20 (8) | |
| Other leukemia | 15 (3.9) | 5 (3.7) | 10 (4) | |
| CML | 5 (1.3) | 2 (1.5) | 3 (1.2) | |
| Histiocytosis | 4 (1) | 2 (1.5) | 2 (0.8) | |
| Hemoglobinopathy | 1 (0.3) | 1 (0.7) | 0 (0) | |
| Other Anemia | 1 (0.3) | 0 (0) | 1 (0.4) | |
| Atypical CML | 1 (0.3) | 0 (0) | 1 (0.4) | |
| Recipient/Donor CMV, n (%) | .55 | |||
| R-/D- | 148 (38.2) | 51 (37.5) | 97 (38.6) | |
| R-/D+ | 86 (22.2) | 27 (19.9) | 59 (23.5) | |
| R+/D- | 84 (21.7) | 30 (22.1) | 54 (21.5) | |
| R+/D+ | 68 (17.6) | 27 (19.9) | 41 (16.3) | |
| Not tested | 1 (0.3) | 1 (0.7) | 0 (0) | |
| HCT-CI, n (%) | .65 | |||
| 0 | 12 (3.1) | 6 (4.4) | 6 (2.4) | |
| 1 | 58 (15) | 18 (13.2) | 40 (15.9) | |
| 2 | 56 (14.5) | 19 (14) | 37 (14.7) | |
| ≥3 | 261 (67.4) | 93 (68.4) | 168 (66.9) | |
| Median (range) | 4 (0, 12) | 4 (1, 10) | 4 (0, 12) | |
| Degree of HLA match, n (%) | .24 | |||
| 8/8 | 333 (86) | 122 (89.7) | 211 (84.1) | |
| 7/8 | 52 (13.4) | 13 (9.6) | 39 (15.5) | |
| 6/8 | 2 (0.5) | 1 (0.7) | 1 (0.4) | |
| Transplant characteristics | ||||
| Conditioning intensity, n (%) | .095 | |||
| Myeloablative | 105 (27.1) | 44 (32.4) | 61 (24.3) | |
| Reduced intensity | 282 (72.9) | 92 (67.6) | 190 (75.7) | |
| GVHD prophylaxis regimen, n (%) | .23∗ | |||
| PTCY | 1 (0.3) | 0 (0) | 1 (0.4) | |
| PTCY/Tacrolimus/Mycophenolate mofetil | 76 (19.9) | 32 (23.5) | 43 (17.9) | |
| Tacrolimus/Methotrexate | 238 (61.5) | 90 (66.2) | 148 (59) | |
| Tacrolimus/Rapamycin | 6 (1.6) | 1 (0.7) | 5 (2) | |
| Tacrolimus/Rapamycin/Methotrexate | 66 (16.8) | 13 (9.6) | 53 (20.7) | |
| Duration of cryopreservation (h), median (range) | 272.7 (48.1, 2855,7) | |||
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin’s lymphoma; CML, chronic myelogenous leukemia.
Comparison of Tacrolimus+methotrexate and/or sirolimus versus PTCY-based GVHD prophylaxis regimen